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Introduction
Platelets are small, anuclear blood cells that are essential for blood 
clotting and the maintenance of vascular integrity (1, 2). They are 
produced by megakaryocytes, large polyploid precursor cells that 
develop primarily in the bone marrow. Megakaryocytes undergo a 
unique process of growth and maturation involving replication of 
DNA without cell division (endomitosis), a massive expansion of 
cytoplasmic volume, and the development of an extensive inter-
nal membranous network known as the demarcation membrane 
system. Upon maturity, megakaryocytes form filamentous protru-
sions termed “proplatelets” that are extruded into the bone mar-
row sinusoids. Evidence suggests platelet biogenesis is the result of 
individual platelets budding off from proplatelets, as well as pro-
platelets themselves being shed and subsequently maturing into 
platelets within the circulation (3). The molecular regulation of this 
unique process of blood cell formation is only partially understood.
The number, cellular volume, and function of platelets are 
tightly regulated within individuals. However, all 3 parameters 
vary widely at the population level, and represent independent 
risk factors for heart attack and stroke (4). Population variation is 
to a large extent explained by common single nucleotide variants 
(SNVs), which exert small effects. Major deviations are triggered 
by rare variants that have effects of sufficient magnitude to cause 
Mendelian platelet disorders. A metaanalysis of genome-wide 
association studies identified 68 independent common SNVs 
associated with platelet count and volume (5). Several of these 
SNVs were linked to genes encoding proteins with well-established 
roles in platelet formation (e.g., THPO [thrombopoietin], GP1BA 
[glycoprotein Ibα], TUBB1 [tubulin-β1]) and survival (the apopto-
sis regulator BAK [encoding BAK]). However, the vast majority of 
identified SNVs were located near genes hitherto uncharacterized 
in the megakaryocyte lineage.
Platelets are anuclear cells that are essential for blood clotting. They are produced by large polyploid precursor cells called 
megakaryocytes. Previous genome-wide association studies in nearly 70,000 individuals indicated that single nucleotide 
variants (SNVs) in the gene encoding the actin cytoskeletal regulator tropomyosin 4 (TPM4) exert an effect on the count 
and volume of platelets. Platelet number and volume are independent risk factors for heart attack and stroke. Here, we have 
identified 2 unrelated families in the BRIDGE Bleeding and Platelet Disorders (BPD) collection who carry a TPM4 variant that 
causes truncation of the TPM4 protein and segregates with macrothrombocytopenia, a disorder characterized by low platelet 
count. N-Ethyl-N-nitrosourea–induced (ENU-induced) missense mutations in Tpm4 or targeted inactivation of the Tpm4 
locus led to gene dosage–dependent macrothrombocytopenia in mice. All other blood cell counts in Tpm4-deficient mice 
were normal. Insufficient TPM4 expression in human and mouse megakaryocytes resulted in a defect in the terminal stages 
of platelet production and had a mild effect on platelet function. Together, our findings demonstrate a nonredundant role for 
TPM4 in platelet biogenesis in humans and mice and reveal that truncating variants in TPM4 cause a previously undescribed 
dominant Mendelian platelet disorder.
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modulating erythrocyte membrane stability (15), virtually nothing 
is known about the roles of tropomyosins in hematopoietic cells.
Here, we demonstrate that, in both humans and mice, TPM4 
is an essential mediator of platelet biogenesis. Genome sequenc-
ing of 865 index cases with bleeding and platelet disorders of 
unknown molecular etiology revealed 2 pedigrees with a prema-
ture stop codon in TPM4. This variant was absent from nearly 
75,000 control DNA samples and segregated with large platelets 
and concomitant low platelet count (a phenotype termed macro-
thrombocytopenia) in the 2 pedigrees. Mutation of murine Tpm4 
resulted in dose-dependent macrothrombocytopenia caused by 
a defect in the terminal stages of platelet production. This was 
recapitulated by shRNA knockdown in human megakaryocytes. 
In addition to a reduction in platelet number and an increase 
in mean platelet volume, a mild defect in platelet function was 
observed in both humans and mice. Our findings demonstrate 
that TPM4 encodes a tropomyosin with an important nonredun-
dant role in platelet biogenesis, and define a novel, dominant, 
Mendelian platelet disorder.
Results
Tropomyosin expression in human and mouse megakaryocytes and 
platelets. Previous RNA sequencing studies have indicated that 
human megakaryocytes express TPM1, TPM3, and TPM4, and low 
levels of TPM2 (ref. 6 and Supplemental Figure 1A; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI86154DS1). We performed reverse transcriptase–PCR (RT- 
PCR), which confirmed these findings, and demonstrated that 
TPM4 is the most highly expressed of the tropomyosins, followed 
by TPM1 (Figure 1A). Western blotting of whole cell lysates demon-
strated the presence of protein products of all 4 tropomyosin genes 
in WT mouse and healthy human control platelets (Figure 1B). The 
short TPM4 30-kDa isoform (TPM4.2) was the major isoform in 
both species. Human platelets additionally appear to harbor small 
amounts of the long 38-kDa TPM4.1 isoform (Figure 1B, top). Here-
after, the term “TPM4” is used to indicate both protein isoforms 
TPM4.1 and TPM4.2 (in humans) or solely TPM4.2 (in mice).
A truncating mutation in TPM4 causes macrothrombocytopenia 
in humans. We next performed a look-up in the database for the 
Biomedical Research Centres/Units Inherited Diseases Genetic 
Evaluation (BRIDGE) Bleeding and Platelet Disorders (BPD) col-
lection. To date, over 1,000 participants have been enrolled and 
genome-sequenced as part of the BRIDGE-BPD study for genome 
sequencing along with approximately 5,000 participants with oth-
er rare diseases enrolled to the NIHR BioResource–Rare Diseases 
(16). Two high-impact rare variants in TPM4.1 and 1 in TPM4.2 
were identified. The variant affecting the product of TPM4.2 was 
a nucleotide substitution of C to T at position 16192795 of chromo-
some 19 (build GRCh37). It was present on 1 allele in 2 unrelated 
BPD cases and was absent from the Exome Aggregation Consor-
tium (ExAC) database (17) as well as the UK10K database (18). The 
2 cases do not share any other rare variants, and their estimated 
genome-wide kinship, based on common unlinked SNVs (19), was 
estimated to be zero, suggesting that the variant did not arise in a 
recent common ancestor.
Predicted loss-of-function variants in TPM4.2 are rare in the 
general population, with only 2 heterozygotes observed among the 
Tropomyosins, which form copolymers with actin, are a prime 
example, with SNVs rs3809566 and rs8109288 marking the genes 
encoding tropomyosin 1 (TPM1) and tropomyosin 4 (TPM4), 
respectively. It has been reported that expression of transcripts 
from the TPM4 locus strongly increases in the later stages of 
megakaryopoiesis (5, 6). In addition, chromatin immunoprecipi-
tation in primary megakaryocytes for 5 transcription factors with 
essential roles in platelet biogenesis revealed that TPM4 contains 
a nucleosome-depleted regulatory element occupied by all 5 fac-
tors (7), placing the gene in a unique category of fewer than 200 
genes. Morpholino knockdown of its homolog tpma in zebrafish 
abolished the formation of thrombocytes, suggesting a functional 
role for TPM4 in mammalian thrombopoiesis (5, 8).
Tropomyosins are ubiquitously expressed and highly con-
served. Mouse and human homologs exhibit greater than 90% 
identity at the amino acid level. In mammals, tropomyosins are 
encoded by 4 different genes: TPM1, TPM2, TPM3, and TPM4. 
Alternative promoter usage and alternative splicing result in 
approximately 40 different TPM protein isoforms in humans 
(reviewed in ref. 9; for nomenclature used in this study, see ref. 
10). Intriguingly, despite their similarity, individual tropomyosin 
genes have largely nonredundant functions, as illustrated by the 
fact that the constitutive deletion of either Tpm1, Tpm2, or Tpm3 
in mice results in embryonic lethality (11–13). Tpm4 knockout mice 
have not previously been described.
The best-characterized tropomyosins are the muscle-specific 
isoforms, which mediate the interaction between myosin and 
actin. In humans, mutations affecting the expression of muscle 
tropomyosins cause familial hypertrophic cardiomyopathy (TPM1) 
and nemaline myopathies (TPM2 and TPM3). These disease phe-
notypes are recapitulated in mice carrying similar mutations (14). 
The “nonmuscle” (or “cytoskeletal”) tropomyosin isoforms are 
often referred to as “gatekeepers,” as they regulate the accession 
of other actin-binding proteins and myosin motors to the actin 
filament (9). The cytoskeletal tropomyosins are implicated in the 
regulation of cell morphology, adhesion, migration, granule traf-
ficking, cell division, and apoptosis. Except for an involvement in 
Figure 1. Tropomyosin expression in human and mouse. (A) Multiple 
TPMs are expressed in human megakaryocytes. Relative TPM mRNA 
expression of human cord blood–derived megakaryocytes was evaluat-
ed by real-time quantitative PCR. Data are presented as mean ± SD of 
3 independent experiments. (B) Comparison of tropomyosin (TPM1–4) 
protein expression between human and WT mouse platelets. Top panel: 
The 30-kDa TPM4 protein isoform (TPM4.2) is the main isoform in both 
human and mouse platelets. Human platelets additionally express low 
amounts of the 38-kDa TPM4 isoform (TPM4.1). Bottom panel: β-Actin 
loading control.
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above 13 fl or if there was presence of macrothrombocytes as 
observed by electron microscopy. The propositus of pedigree 1 car-
rying the premature stop codon was a woman of mixed European 
descent who was enrolled to the BRIDGE-BPD study at 56 years 
old with a history of mild bleeding (see Supplemental Methods for 
full clinical history) consistent with observed platelet counts in the 
range of 80 × 109 to 110 × 109 per liter. Other than breast carcino-
ma, there was no other relevant past medical history. Analysis of 2 
more than 60,000 individuals in ExAC (1 with a splice site variant 
and 1 with a variant encoding a premature stop at residue 54). The 
variant concerning the BPD patients encodes a premature stop 
codon in exon 3 of TPM4, resulting in a truncation at residue 69 of 
the major protein isoform TPM4.2, and residue 105 of the minor 
isoform TPM4.1 (Figure 2A).
Macrothrombocytopenia was deemed present if the platelet 
count was below 150 × 109 per liter or the mean platelet volume 
Figure 2. TPM4 mutation causes 
macrothrombocytopenia in humans. 
(A) Schematic representation of the 
major megakaryocyte TPM4 transcript 
ENST00000300933, which is predicted 
to encode the 248–amino acid TPM4 
protein (UniProt ID P67936). R69 is 
transcribed from the second exon of 
the transcript and is 68 amino acids 
from the amino-terminus of TPM4. 
R69X is predicted to cause expression 
of a truncated TPM4 protein. (B) Fam-
ily trees for pedigree 1 and pedigree 2 
with the TPM4 variant are depicted, 
including the platelet count, platelet 
volume, and presence/absence (Y/N) 
of macrothrombocytes when visual-
ized by electron microscopy (shown 
in blue). Filled symbols: macrothrom-
bocytopenia; gray symbols, unknown; 
open symbols: normal platelet count 
and volume and absence of macro-
thrombocytes. +/M, heterozygous; 
+/+, WT. (C) Platelet TPM4 RNA levels 
measured by RT-PCR using GAPDH 
as housekeeping gene. Graph depicts 
representative data from a total of  
n = 3 measurements from 1 (case 1-II-
5) or 3 (case 1-III-7) patient samples. 
(D) Platelet TPM4 protein is reduced 
in heterozygous carriers of the TPM4 
variant. Graph depicts representative 
data from a total of n = 3 measure-
ments from 1 (case 1-II-5) or 3 (case 
1-III-7) samples. Left: Densitometry 
analysis performed using ImageJ. 
Right: Protein levels of platelet TPM4 
in controls and cases 1-II-5 and 1-III-7. 
β-Actin was included as an internal 
loading control. Similar results were 
obtained when GAPDH was used as 
a loading control (not shown). (E) 
Sex-stratified histograms of platelet 
count (PLT) and mean platelet volume 
measurements obtained using a Sys-
mex hematology analyzer from 48,345 
blood donors from the INTERVAL 
study after adjustment for technical 
artifacts. The red arrows superimposed 
on the histograms indicate the sex 
of and values for patients with the 
truncating variant in TPM4. The green 
arrows indicate the sex of and values 
for relatives homozygous for the corre-
sponding WT allele.
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protein in 2 of 3 affected pedigree members (Supplemental Figure 
1D). The sex-stratified quantiles of mean platelet volume mea-
surements with respect to the INTERVAL study (measurements 
obtained using a Sysmex hematology analyzer from 48,345 blood 
donors) were all above 91%, with 3 of the 5 measurements at per-
centiles exceeding 99.9% (20). This indicates that the platelets of 
the carriers are consistently large, with some extremely large. The 
sex-stratified quantiles of the platelet count (PLT) measurements 
with respect to INTERVAL were below 4% in all cases except the 
index case of pedigree 2, with 3 of the 5 measurements at percen-
tiles below 1%. In contrast, all the WT homozygotes had PLT quan-
tiles between 23% and 82% (Figure 2E). The probability of observ-
ing cosegregation under the null hypothesis that the mutant is not 
causal, conditional on having already observed the mutant in the 
propositi, is 0.53 for each pedigree, and P = 0.0156 in total. Collec-
tively, these data provide convincing evidence that loss-of-function 
variants in TPM4 can cause macrothrombocytopenia, and suggest 
it plays a role in the development of the megakaryocyte lineage.
A loss-of-function allele of murine Tpm4 causes macrothrombo-
cytopenia. In parallel studies, we conducted an N-ethyl-N-nitro-
sourea (ENU) mutagenesis screen in mice for mutations caus-
ing dominant thrombocytopenia (21, 22). A mouse exhibiting a 
decrease in platelet number and increase in mean platelet vol-
ume was identified and named Plt53. Fifty percent of the progeny 
from this animal also exhibited macrothrombocytopenia. After 
backcrossing, exome sequencing of 2 affected animals followed 
by genotyping of candidate mutations in siblings and offspring 
revealed that the Plt53 phenotype correlated with inheritance of 
a point mutation in the gene encoding TPM4. The mutation, at 
nucleotide g.72,147,268, was a substitution of A for G in the first 
dinucleotide of the donor splice site in exon 7 of the Tpm4 gene 
(hereafter referred to as Tpm4Plt53/Plt53). RT-PCR analysis of cDNA 
extracted from megakaryocytes revealed that the Plt53 mutation 
led to the inclusion of part of intron 7 in the Tpm4 mRNA. The pre-
dicted result is a protein bearing 8 intron-encoded amino acids fol-
lowed by premature truncation due to the presence of an in-frame 
stop codon at nucleotide g.72,147,291 (Figure 3A).
Western blotting with an antibody raised against the TPM4 
C-terminus (δ/9d) revealed the complete absence of TPM4 in 
Tpm4Plt53/Plt53 platelets, and reduced expression in Tpm4Plt53/+ plate-
lets (Figure 3B, top). The lower band observed with this antibody 
was not detected with 2 other TPM4 antibodies and is therefore 
most likely unspecific (Supplemental Figure 2A). Using an N-ter-
siblings and the propositus’ daughter demonstrated segregation of 
the observed variant with macrothrombocytopenia (Figure 2B and 
Supplemental Figure 1B). The propositus (1-II-5) and her daugh-
ter (1-III-7) exhibited platelet counts lower than those of the unaf-
fected siblings (103 × 109 and 140 × 109 per liter compared with 
226 × 109 and 236 × 109 per liter, respectively) with mean plate-
let volumes well above 13 fl. All other blood counts were within 
normal range (Table 1), suggesting a specific role for TPM4 in the 
megakaryocyte lineage.
The propositus of pedigree 2 was a woman of mixed European 
descent enrolled in the BRIDGE-BPD study at 58 years of age. She 
had a platelet count of 230 × 109 per liter with a platelet volume 
near the upper limit of normal (12.9 fl). Macrothrombocytes were 
observed by electron microscopy. She had suffered with menor-
rhagia from menarche that did not improve upon hormonal thera-
py and therefore required recurrent dilatation and curettages, and 
finally a hysterectomy at the age of 37 (see Supplemental Meth-
ods for full clinical history). Platelet function tests including von 
Willebrand parameters and coagulation factors (IX, XI, and XIII) 
revealed no abnormality. Other than severe asthma and eczema, 
there was no past medical history of note. Analysis of 3 of the prop-
ositus’ children demonstrated segregation of the observed variant 
with a lower platelet count and larger platelets (Figure 2B and Sup-
plemental Figure 1C). Pedigree member 2-III-5, who carries the 
variant, had a platelet count and mean platelet volume just with-
in the normal range (160 × 109 per liter and 12.3 fl, respectively). 
He experienced no abnormal bleeding in response to a number of 
hemostatic challenges, including a laparotomy, orchiopexy, and 4 
dental extractions. His sibling (2-III-7), who also carries the muta-
tion, exhibited a low platelet count (146 × 109 per liter) and large 
mean platelet volume (14.6 fl), and a bleeding tendency similar to 
the propositus’ (see Supplemental Methods for full clinical histo-
ry). 2-III-6 does not carry the variant and had the highest platelet 
count (278 × 109 per liter) and lowest mean platelet volume (10.8 
fl) of all family members. Thus, the variant cosegregates with iso-
lated macrothrombocytopenia.
TPM4.2 mRNA levels were reduced to 59% and 78% of the 
control in the affected cases 1-II-5 and 1-III-7, respectively (Fig-
ure 2C), and a corresponding approximately 50% reduction in 
the expression of TPM4.2 protein was observed with an antibody 
raised against the TPM4 C-terminus (δ/9d) (Figure 2D). Pedigree 2 
exhibited similar defects, with mRNA levels reduced to 46%–63%, 
and we were able to detect a corresponding reduction in TPM4.2 
Table 1. Blood counts of cases of families 1 and 2 carrying the TPM4 variant, including the depiction of normal count variation
Parameter 1-II-5 1-III-7 2-II-3 2-III-5 2-III-6 2-III-7 Normal range
rbc (×1012/liter) 4.72 4.52 4.84 5.29 5.50 4.68 3.80–4.80
HCT (%) 42 41 45 49 49 43 37–45
Lymphocytes (×109/liter) 1.31 1.82 1.4 1.4 1.8 1.5 1.00–4.00
Neutrophils (×109/liter) 3.68 4.67 3.9 2.9 3.0 7.9 1.50–7.50
Basophils (×109/liter) 0.03 0.02 0.1 0.0 0.1 0.1 <0.11
Monocytes (×109/liter) 0.24 0.7 0.4 0.6 0.4 0.7 0.20–1.00
Eosinophils (×109/liter) 0.07 0.05 0.3 0.1 0.1 0.1 <0.51
Measurements obtained using a Sysmex hematology analyzer. HCT, hematocrit.
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tically significant (P = 0.0008), increase in lymphocyte counts in 
the Tpm4Plt53/Plt53 cohort (Table 2). Flow cytometric analysis of bone 
marrow revealed normal numbers of immunophenotypic hema-
topoietic progenitor cells, including megakaryocyte progenitors, 
in Tpm4Plt53/Plt53 mice (Table 3). Transplantation of unfractionated 
bone marrow from Tpm4Plt53/Plt53 animals into lethally irradiated 
adult recipients resulted in macrothrombocytopenia (Supplemen-
tal Figure 2B), demonstrating that the phenotype was intrinsic to 
the hematopoietic system. To confirm the Plt53 mutation as the 
causative genetic lesion, we generated an independent knock-
out mouse strain for TPM4.2, the only TPM4 protein isoform 
expressed in mice. Strikingly, given the early lethality observed 
in Tpm1, Tpm2, and Tpm3 knockouts, animals lacking Tpm4 were 
viable and outwardly healthy. They exhibited a dose-dependent 
macrothrombocytopenia (Figure 3D and Supplemental Figure 3, 
minal specific antibody (δ/1b), we observed a faint band of lower 
molecular weight in platelets from heterozygous and homozygous 
mutant mice, indicating the presence of some residual truncated 
TPM4 protein (Figure 3B, middle). Given that the overlap of N- 
and C-termini of TPM dimers is essential for filament formation 
(23), these data indicated that the Plt53 allele of Tpm4 represents a 
complete loss of the protein’s canonical function.
Heterozygous (Tpm4Plt53/+) and homozygous (Tpm4Plt53/Plt53) 
animals appeared healthy, and histopathological examination 
revealed no obvious organ abnormalities or pathology. Relative to 
WT littermates, Tpm4Plt53/+ mice exhibited mild macrothrombocy-
topenia (Figure 3C), and Tpm4Plt53/Plt53 animals a more severe form, 
with approximately 50% reduction in platelet counts. Remarkably, 
other peripheral blood cell counts in Tpm4Plt53/+ and Tpm4Plt53/Plt53 
mice were unchanged, with the exception of a modest, but statis-
Figure 3. Loss of function at the Tpm4 locus causes macrothrombocytopenia in mice. (A) Schematic representation of the Plt53 mutation (A to G sub-
stitution at nucleotide g.72,147,268) in the first dinucleotide of the donor splice site in exon 7 of Tpm4, which is predicted to result in a protein bearing 8 
intron-encoded amino acids followed by premature truncation due to the presence of an in-frame stop codon at nucleotide g.72,147,291. (B) Top panel: Use 
of an antibody directed against the TPM4 C-terminus (δ/9d, AB5449, Millipore) demonstrates that TPM4.2 is not expressed in Tpm4Plt53 platelets. Middle 
panel: Use of an antibody directed against the TPM4 N-terminus (δ/1b) reveals residual expression of a truncated TPM4.2 protein from the Tpm4Plt53  
allele (orange arrow). Bottom panel: β-Actin loading control. Results are representative of 3 independent experiments. (C) The Plt53 mutation causes  
macrothrombocytopenia. Reduced platelet count and increased platelet size in Tpm4Plt53/+ and Tpm4Plt53/Plt53 mice compared with Tpm4+/+ mice (n = 17).  
(D) Platelet count and size in Tpm4.2 WT (+/+), heterozygous (+/–), and homozygous knockout (–/–) mice (n = 10–15) on a C57BL/6 background. Measure-
ments were performed using an Advia hematology analyzer. One-way ANOVA, unpaired 2-tailed Student’s t test with Bonferroni correction for multiple 
comparisons. *P < 0.05, ***P < 0.001.
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A–C), similar in magnitude to that observed in Tpm4Plt53 mutants 
on a C57BL/6 background (the background on which the targeted 
knockout allele was generated) (Supplemental Figure 3D). Togeth-
er, these data demonstrate a specific requirement for TPM4 in the 
megakaryocyte lineage.
TPM4 insufficiency results in aberrant platelet morphology. 
Transmission electron microscopy (TEM) analysis of platelets 
from the 2 affected cases from pedigree 1 revealed considerable 
heterogeneity in platelet size, some of them being very large. We 
also observed an increased presence of large vacuoles (Figure 4, 
A and B). Blinded analysis of TEM pictures correctly identified all 
the carriers from pedigree 2. Platelets from 2-II-3 and 2-III-5 exhib-
ited moderate defects (Supplemental Figure 4) similar to those 
observed for pedigree 1 (Figure 4, A and B). Platelets from 2-III-7 
were obviously different from the control, with an increased small 
diameter and an ellipsoid rather than discoid shape.
Consistent with the human data, TEM analysis revealed 
considerable heterogeneity in the size and morphology of 
Tpm4Plt53/Plt53 and Tpm4Plt53/+ platelets, with frequent vacuoles, indi-
cating increased fragility of the mutant platelets (Figure 4C). Giv-
en that ultra-rare variants in FLNA (the gene encoding filamin A) 
have recently been reported to result in fragile platelets and mac-
rothrombocytopenia (24), and variants in the actin–cross-linking 
protein actinin 1 (α-actinin, ACTN1) are one of the most frequent 
causes of isolated thrombocytopenia with altered platelet mor-
phology (25–27), we examined the levels of these 2 proteins. Inter-
estingly, we found that filamin A was partially 
degraded in Tpm4Plt53/Plt53 and to a lesser extent 
Tpm4Plt53/+ platelets (Figure 4D, top). Levels of 
full-length actinin 1 were reduced in Tpm4Plt53/Plt53 
and Tpm4Plt53/+ platelets, coinciding with the 
appearance of an 80-kDa band that has been 
previously reported to be the result of cleavage 
by calpain (Figure 4D, bottom) (28).
Reduced TPM4 expression impacts platelet 
function. We next examined the function of 
the platelets of the daughter of the proposi-
tus of pedigree 1 (case 1-III-7 in Figure 2B). 
In response to any of the agonists ADP, cross-
linked collagen-related peptide (CRP-XL), and 
TRAP-6, no significant differences in platelet 





tion and α-granule secretion were revealed 
(Figure 5A). However, when thrombus forma-
tion under flow ex vivo was examined, both 
the number of thrombi and the area covered 
were reduced in case 1-III-7 relative to the con-
trol (P < 0.001) (Figure 5, B and C).
We then probed the impact of TPM4 
dysfunction on platelet function in mice. 
Given that macrothrombocytopenia can be 
triggered by accelerated platelet clearance, 
we firstly examined the in vivo lifespan of 
Tpm4+/+, Tpm4Plt53/+, and Tpm4Plt53/Plt53 plate-
lets. No change in the kinetics of clearance 
or ultimate lifespan was observed, indicating 
that lack of functional TPM4 did not affect 
platelet turnover (Figure 6A). Platelet activation was assessed 




 activation (JON/A 
antibody) and α-granule secretion (anti–P-selectin antibody) as 
markers. Tpm4Plt53/+ and Tpm4Plt53/Plt53 platelets were responsive 
to a range of agonists, indicating that the processes of integrin 
inside-out activation and degranulation are functional in the 
absence of TPM4 (Figure 6B and Supplemental Figure 5A). The 




 in the 
Tpm4Plt53/Plt53 samples was most probably due to the increased size 
of the mutant platelets, as it correlated with an approximately 37% 
increase in basal CD41 (integrin α
IIb
 subunit) fluorescence signal 
(Figure 6B and Supplemental Table 1). To investigate the involve-
ment of TPM4 in activation-induced morphological changes, we 
incubated thrombin-activated Tpm4+/+ and Tpm4Plt53/Plt53 platelets 
on fibrinogen-coated coverslips. Under these conditions, plate-
lets from both genotypes fully spread, but the spreading process 
was significantly delayed in the mutant (Figure 6C). As seen with 
case 1-III-7, thrombus formation on collagen under flow ex vivo 
was significantly reduced in blood from Tpm4Plt53/Plt53 mice (Fig-
ure 6D and Supplemental Figure 5B). Finally, we found that tail 
bleeding times were mildly extended in Tpm4Plt53/Plt53 mice, and in 
lethally irradiated C57BL/6 mice with transplanted Plt53/Plt53 
bone marrow, relative to their respective controls (P = 0.165 and 
P = 0.045; Figure 6E and Supplemental Figure 5C). Togeth-
er, these results demonstrate that the hemostatic function of 
TPM4-deficient platelets is mildly compromised.
Table 2. Blood counts of adult Tpm4+/+, Tpm4Plt53/+, and Tpm4Plt53/Plt53 mice
Parameter +/+ +/Plt53 Plt53/Plt53
rbc (×106/ml) 11.8 ± 0.4 12.0 ± 0.4 (NS) 11.6 ± 0.3 (NS)
HCT (%) 62.6 ± 3.0 63.7 ± 2.2 (NS) 62.6 ± 1.9 (NS)
Lymphocytes (×103/ml) 8.7 ± 1.7 9.1 ± 1.0 (NS) 10.7 ± 1.5A
Neutrophils (×103/ml) 1.4 ± 0.4 1.5 ± 0.3 (NS) 1.7 ± 0.5 (NS)
Basophils (×103/ml) 0.10 ± 0.04 0.12 ± 0.02 (NS) 0.12 ± 0.03 (NS)
Monocytes (×103/ml) 0.15 ± 0.06 0.15 ± 0.04 (NS) 0.18 ± 0.05 (NS)
Eosinophils (×103/ml) 0.19 ± 0.07 0.17 ± 0.08 (NS) 0.16 ± 0.08 (NS)
Determined with an Advia hematology analyzer (n = 17). Unpaired 2-tailed Student’s t test with 
Bonferroni correction for multiple comparisons. AP < 0.01. HCT, hematocrit.
Table 3. Analysis of blood progenitor populations in the bone marrow of adult 
Tpm4+/+ and Tpm4Plt53/Plt53 mice by flow cytometry (n = 3)
Parameter Marker +/+ Plt53/Plt53
LSK (×104) Lin–Kit+Sca1+ 1.6 ± 0.3 2.2 ± 0.5 (NS)
MEP (×104) Lin–Kit+Sca1–CD34–CD16/32lo 6.6 ± 0.8 6.3 ± 1.3 (NS)
MkP (×104) Lin–Kit+Sca1–CD150+CD41+ 1.8 ± 0.3 1.8 ± 0.7 (NS)
CMP (×104) Lin–Kit+Sca1–CD34+CD16/32lo 5.1 ± 0.8 4.8 ± 1.2 (NS)
GMP (×104) Lin–Kit+Sca1–CD34+CD16/32hi 17.3 ± 1.9 18.6 ± 4.4 (NS)
Lineage (Lin) markers included CD4, CD8, CD11b, CD19, B220, Gr1, Ter119, F4/80, and CD11b. 
The absolute cell number is shown. Unpaired 2-tailed Student’s t test. MkP, megakaryocyte 
progenitors. LSK, lineage-negative (Lin–), Sca-1+, c-Kit+ cells; MEP, megakaryocyte–erythroid 
progenitor; CMP, common myeloid progenitor; GMP, granulocyte-macrophage progenitor.
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TPM4 localizes to proplatelets in human and mouse megakaryo-
cytes. Sorting of tropomyosin isoforms to different cellular com-
partments is thought to be crucial for their function (9). TPM4 
localized to proplatelets and colocalized with filamentous (F) 
actin in primary CD34+-derived human megakaryocytes (Figure 
7A). In mature, WT mouse megakaryocytes, TPM4 showed a dif-
fuse, mainly peripheral distribution and did not obviously colo-
calize with F-actin (Figure 7B). As expected, we could not detect 
TPM4 in Tpm4Plt53/Plt53 megakaryocytes using the δ/9d antibody 
(Supplemental Figure 6A). The distribution and morphology of 
F-actin and tubulin were similar in mature WT and Tpm4Plt53/Plt53 
megakaryocytes (not shown). In WT megakaryocytes commenc-
ing proplatelet formation, TPM4 was organized in a fine punctu-
ate network (Supplemental Figure 6B). TPM4 colocalized with 
actin in proplatelet swellings and tips and partially at proplatelet 
membranes (Figure 7C).
TPM4 facilitates proplatelet formation in human and mouse. We 
next examined the effect of depleting TPM4 in human megakary-
ocytes derived from CD34+ hematopoietic progenitor cells. While 
megakaryocyte proliferation and maturation were unaffected by 
transduction with shRNAs targeting TPM4 (Supplemental Figure 
7A), the level of proplatelet formation was reduced in compari-
son with the nontargeting control. ShRNA_TPM4B and shRNA_ 
TPM4E, which knocked down mRNA levels to approximately 20% 
and 8%, respectively, reduced proplatelet formation by approxi-
mately 40% and 14%. Logistic regression analysis showed that 
the correlation between the proportion of proplatelet-forming 
cells and RNA and protein levels for TPM4 was highly significant 
(P < 2–16 and < 6.23–12, respectively) (Figure 8A), demonstrating that 
the level of TPM4 is rate-limiting for platelet formation.
In mice, we observed a significant increase in megakaryocyte 
numbers in Tpm4Plt53/+ and Tpm4Plt53/Plt53 bone marrow (Figure 8B). 
Ploidy profiles were unchanged (Supplemental Figure 7B). How-
ever, mutant megakaryocytes were smaller than WT counterparts 
(~20% of Tpm4Plt53/+ and ~30% of Tpm4Plt53/Plt53 compared with only 
~4% of Tpm4+/+ megakaryocytes were smaller than 50 μm2), and 
many exhibited an irregular morphology (Figure 8, C and D). Rel-
ative to the WT, proplatelet formation was reduced by approxi-
mately 40% in fetal liver–derived Tpm4Plt53/Plt53 megakaryocytes 
and by approximately 20% in Tpm4Plt53/+ cells (Figure 8E). Time-
lapse video microscopy indicated that, while the initial morpho-
logical changes associated with proplatelet formation took place in 
mutant cells, loss of TPM4 resulted in megakaryocytes with few or 
no branches (Figure 8F and Supplemental Videos 1 and 2). Where 
proplatelets did form, their tips were significantly increased in size 
relative to WT counterparts (Supplemental Figure 7C). Visualiza-
tion of F-actin and tubulin demonstrated that within the short, 
thick branches produced by Tpm4+/+ megakaryocytes, massive 
Figure 4. TPM4 insufficiency results in altered platelet morphology. (A and B) Ultrastructure of platelets from cases 1-II-5 and 1-III-7 carrying the variant, 
showing the presence of large platelets with numerous vacuoles indicating increased fragility, contrasting the normal discoid platelet appearance in con-
trols. (A) Overview. (B) Detail. Scale bars: 1 μm. (C) Representative electron microscopic pictures illustrating increased size and fragile appearance in  
Tpm4Plt53/Plt53 and Tpm4Plt53/+ compared with Tpm4+/+ platelets (n = 2; each sample was pooled from 2 individuals). Scale bars: 1 μm. (D) Western blot 
showing the presence of degraded filamin A and actinin 1 in Tpm4Plt53/Plt53 and Tpm4Plt53/+ compared with Tpm4+/+ platelets. Results are representative of 2 
independent experiments. Bottom panel: β-Actin loading control.
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nia, and have been linked to the RHOA/ROCK pathway (33). We 
therefore examined the expression and phosphorylation state of 
RHOA, ROCK, and NMMHC-IIa by Western blot. No differenc-
es between Tpm4Plt53/Plt53, Tpm4Plt53/+, and Tpm4+/+ megakaryocytes 
and platelets were observed (Supplemental Figure 10A). Confo-
cal microscopy of Tpm4+/+ megakaryocytes undergoing the first 
morphological changes presaging proplatelet formation revealed 
that NMMHC-IIa localized to a fine network (Supplemental 
Figure 10B), very similar to the distribution of TPM4 (Supple-
mental Figure 6B). This pattern was dramatically perturbed in 
approximately 50% of Tpm4Plt53/Plt53 megakaryocytes. In WT pro-
platelet swellings and tips, NMMHC-IIa localized to a previously 
described characteristic network and to membranes (Figure 9C, 
left, and ref. 34). In contrast, NMMHC-IIa in Tpm4Plt53/Plt53 pro-
platelet-forming megakaryocytes showed a patchy distribution in 
approximately 70% of cells analyzed, as compared with approx-
imately 15% of Tpm4+/+ counterparts (Figure 9C, right). These 
results indicate that TPM4 deficiency impacts multiple regulators 
of the megakaryocyte actin cytoskeleton.
Discussion
Cytoskeletal reorganizations are the driving force for the produc-
tion of platelets by megakaryocytes (35). Here, we show that TPM4, 
previously identified by genome-wide association studies as a can-
didate gene correlated to platelet count and volume, is a modulator 
of platelet production. TPM4 insufficiency causes macrothrombo-
cytopenia in mice and humans in a dose-dependent manner.
The tropomyosin genes and particularly TPM4 are highly 
expressed in human and murine megakaryocytes, and the corre-
networks of tubulin were diffusely distributed throughout the cell 
(Figure 8F). Collectively, these data demonstrate an essential role 
for TPM4 in platelet shedding and sizing.
Potential TPM4-interacting proteins in megakaryocytes and 
platelets. Tropomyosins have been reported to interact with sev-
eral proteins that regulate platelet biogenesis. We examined the 
actin filament–severing proteins actin-depolymerizing factor 
(ADF) and cofilin, as these have been shown to directly compete 
with tropomyosins for actin binding (29). While ADF expression 
was unaltered in Tpm4 mutant mouse megakaryocytes and plate-
lets (data not shown), the levels of phosphorylated (inactive) cofi-
lin in Tpm4Plt53/Plt53 cells were significantly decreased (Figure 9, A 
and B). This suggested enhanced actin turnover in mutant cells. 
Consistent with this, a reduction in F-actin levels was observed in 
nonstimulated mutant platelets (Supplemental Figure 8).
Given that TPM4 localization was reported to be abnormal 
in proplatelet tips deficient in tropomodulin 3 (TMOD3) (30), 
we investigated TMOD3 localization in cultured Tpm4+/+ and 
Tpm4Plt53/Plt53 megakaryocytes. In line with that study, we observed 
that TMOD3 localized as puncta with proplatelet membranes 
(Supplemental Figure 9). While TMOD3 appeared to be more 
diffusely distributed in some Tpm4Plt53/Plt53 proplatelets, we did not 
detect major alterations between the mutant and control samples. 
Besides their well-known interaction with tropomodulins, tropo-
myosins have also been demonstrated to recruit myosin IIa to 
stress fibers, and to be involved in stabilization of RHOA (31, 32). 
Inherited mutations in the MYH9 gene, which encodes nonmuscle 
myosin heavy chain IIa (NMMHC-IIa), give rise to the “MYH9- 
related disorders,” all of which exhibit macrothrombocytope-
Figure 5. The function of human platelets is mildly affected by reduced TPM4 expression. (A) Platelet function testing measuring fibrinogen binding 
(top) and P-selectin expression (bottom) (percentage of positive platelets) after treatment with final concentrations of 0.0005 μM ADP, 0.3 μg/ml CRP-
XL, or 0.8 μM TRAP-6. Depicted are the results obtained on 3 different days (2 technical replicates) for the day control and the patient (case 1-III-7). A 
bank of 20 controls is shown in white. (B and C) Thrombus formation on collagen under flow (shear rate 1,600/s). (B) Normalized thrombus number and 
coverage after blood perfusion through a collagen-coated chamber; 6 images captured per run, 2 runs per sample using 2 different samples. (C) Represen-
tative images of thrombi stained with P-selectin captured using fluorescence microscopy (EVOS system; Advanced Microscopy Group). Scale bars: 50 μm. 
Unpaired 2-tailed Student’s t test, ***P < 0.001.
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Our results indicate that TPM4 
insufficiency affects multiple cyto-
skeletal regulators with known roles 
in platelet production, including 
cofilin, myosin IIa, actinin 1, and fil-
amin A. The abnormal distribution 
of tubulin, polymerization of which 
is considered a driving force for 
proplatelet elongation (2, 40), was 
potentially a downstream effect. 
Despite recent work suggesting that 
capping of TPM4-bound actin fil-
aments by TMOD3 is required for 
proplatelet formation (30), TMOD3 
localization was not obviously 
affected in Tpm4 mutant proplate-
lets. This might be explained by 
TPM1 or TPM3.1 partially compen-
sating for the lack of TPM4 during 
proplatelet formation.
Mice lacking cofilin in the 
megakaryocyte lineage display 
macrothrombocytopenia (41), sug-
gesting that the correct balance 
between TPM4 and cofilin is essen-
tial for the production of correct-
ly sized platelets. The decreased 
levels of inactive, phosphorylated, 
cofilin in Tpm4 mutant megakary-
ocytes and platelets are consistent 
with previous studies demonstrat-
ing that tropomyosin and cofilin 
compete with each other at the actin 
filament (29), and indicate that 
reduced TPM4 expression facili-
tates increased binding of active 
cofilin to actin filaments. Mutations 
in the gene encoding NMMHC-IIa 
(MYH9) in cases with MYH9-relat-
ed disorders cause autosomal dominant macrothrombocytopenia 
and bleeding associated with other complex pathobiologies (42). 
Altered localization of NMMHC-IIa was observed in a large pro-
portion of Tpm4 mutant megakaryocytes. This finding is in accor-
dance with a previously established role for TPM4.2 in myosin II 
recruitment to stress fiber precursors (31) and its specific regula-
tory impact on NMMHC-IIa (43).
Reduced TPM4 expression resulted in the production of large 
platelets with fragile appearance (Figure 4 and Supplemental Fig-
ure 4). Fragile platelets with impaired function are a character-
istic of patients with FLNA mutations (24, 44), and of Flna-null 
mice (45). We observed increased levels of degraded filamin A in 
Tpm4 mutant platelets. Interaction of filamin A with glycoprotein 
(GP1B), a component of the VWF receptor complex, is important 
for regulation of platelet size, as well as platelet adhesion and 
maintenance of membrane integrity under high shear (46–48). 
Thus, disturbances in interactions between filamin A and F-actin 
may contribute to the altered size and function of TPM4- 
sponding proteins are abundant in platelets (Figure 1). Our study 
demonstrates that relatively modest alterations in TPM4 dosage 
are sufficient to impact platelet biogenesis. The level of TPM4 
expression in megakaryocytes determines their ability to produce 
correctly sized platelets. Our findings strongly suggest that TPM4 
localization and interaction with actin filaments and other cyto-
skeletal components facilitate megakaryocyte branching during 
proplatelet formation. It has been previously reported that TPM4.2 
overexpression in a neuronal cell line augmented branch forma-
tion (36). Both proplatelet formation and neurite branching require 
extensive localized cytoskeleton-membrane interactions. In line 
with this, recent reports have shown that TPM4.2-bound actin 
filaments are found at membrane regions with specialized func-
tions, such as the postsynaptic membrane (37), the external face of 
the sarcoplasmic reticulum (38), or podosomes (39). Our findings 
therefore suggest that the amount of available TPM4-bound actin 
filaments in megakaryocytes directly determines the amount of 
membrane regions, which can generate proplatelet branches.
Figure 6. The function of mouse platelets is mildly affected by reduced TPM4 expression. (A) Normal in 
vivo lifespan of Tpm4Plt53/+ and Tpm4Plt53/Plt53 compared with Tpm4+/+ platelets. Platelets were labeled by i.v. 
injection with X-488 antibody (Emfret), and the percentage of fluorescent platelets was monitored over time 





 activation (JON/A–PE antibody) in Tpm4+/+, Tpm4Plt53/+, and Tpm4Plt53/Plt53 platelets after activa-
tion with the depicted agonists (n = 4, representative of 3 independent experiments). (C) Platelet spreading. 
Left: Representative differential interference microscopy images of Tpm4+/+ and Tpm4Plt53/Plt53 platelets spread 
on fibrinogen (100 μg/ml) after activation with 0.01 U/ml thrombin. Scale bar: 5 μm. Right: Percentage of 
fully spread Tpm4+/+ (black) and Tpm4Plt53/Plt53 (blue) platelets at 15, 30, and 60 minutes after induction of the 
spreading process (n = 3). Results are representative of 3 independent experiments. (D) Thrombus formation 
on collagen under flow (shear rate 1,000/s). Left: Mean surface covered with thrombi. Right: Relative platelet 
deposition, as measured by integrated fluorescent intensity per square millimeter ± SD. Each dot represents 
an individual. Results are pooled from 2 independent experiments. (E) Tail bleeding times in Tpm4Plt53/+ (blue) 
and Tpm4Plt53/Plt53 (light blue) compared with Tpm4+/+ (black) mice. Each dot represents an individual. Unpaired 
2-tailed Student’s t test, *P < 0.05, **P < 0.01.
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fertile was very surprising, standing in stark contrast to mice lack-
ing Tpm1, Tpm2, or Tpm3, which die in utero (11–13). Thus, TPM4 
is the only tropomyosin family member dispensable for develop-
ment. It plays an essential and highly specific role in F-actin orga-
nization in the megakaryocyte lineage. Given the exceptionally 
high level of conservation between them, the inability of other 
tropomyosin isoforms to fully compensate for the loss of TPM4 
deletion highlights a profound gap in our understanding of how 
functional specificity is achieved and governed.
Methods
Mice
Generation of mice with a mutant Tpm4 allele. Mice carrying a mutant 
Tpm4 allele, named Plt53, were generated. Briefly, male BALB/c mice 
were injected i.p. with 85 mg/kg ENU weekly for 3 weeks (50). Treat-
ed animals were rested for 12 weeks before mating with untreated 
BALB/c females to produce first-generation progeny. Peripheral 
blood was taken from these mice at 7 weeks of age and a complete 
blood cell count performed using an Advia 2120 hematological ana-
lyzer. Animals exhibiting aberrant platelet counts were test-mated 
to determine heritability of the phenotype. Mutant strains were 
backcrossed for 10 generations to the BALB/c background in order 
to breed out irrelevant ENU-induced mutations. Tpm4Plt53/+ mice 
were intercrossed to yield Tpm4+/+, Tpm4Plt53/+, and Tpm4Plt53/Plt53 lit-
termates, which were used in experiments. Mice were 7 to 12 weeks 
old or as otherwise stated.
deficient platelets. Tpm4 mutant platelets also exhibited partial 
degradation of actinin 1. Mutations in the latter cause autosomal 
dominant thrombocytopenia (25–27). Prior studies have suggest-
ed that the levels of actin-binding proteins correlate with fluctu-
ations in tropomyosin isoforms (36, 49). Our work indicates that 
loss of TPM4 binding inhibits binding of other proteins, such 
as filamin A and actinin 1, to actin filaments. This results in an 
impairment of the complex actomyosin cytoskeletal network that 
drives proplatelet formation.
TPM4 insufficiency affected neither the in vivo platelet lifes-
pan in mice, nor the in vitro platelet functional responses to ago-
nists in humans and mice. The delayed spreading observed in 
Tpm4 mutant platelets may be attributed to their increased size, 
but may also indicate specific defects upon decreased TPM4 





signaling (Figure 7C). Consistent with this, mutant mice, and WT 
mice with transplanted mutant bone marrow, tended toward pro-
longed tail bleeding times. Furthermore, thrombus formation on 
collagen under flow by TPM4-deficient platelets of both human 
and mouse origin was reduced. Since the platelet disorder associ-
ated with the TPM4 variant results in an unpredictable bleeding 
phenotype, these findings indicate that reduced levels of TPM4 
result in a mild impairment of hemostasis.
Our findings indicate that, like the targeted knockout, the 
TPM4 variants we identified in both humans and mice result in a 
complete loss of function at the TPM4 locus. The fact that mice 
homozygous for the Plt53 mutation or null allele are healthy and 
Figure 7. TPM4 localizes to proplatelets in 
human and mouse megakaryocytes. (A) 
Immunolabeling of TPM4 (red), F-actin (purple), 
α-tubulin (green), and merge of TPM4/F-actin/ 
α-tubulin and DAPI, in control human pro-
platelets. Scale bar: 25 μm. (B) Investigation of 
TPM4 (yellow) and F-actin (red) localization of 
mouse fetal liver cell–derived megakaryocytes 
by confocal immunofluorescence microscopy. 
TPM4 (yellow) localizes to the periphery in 
mature round WT Tpm4+/+ megakaryocytes. 
(C) TPM4 is enriched in proplatelet tips and 
colocalizes with F-actin (depicted by arrows). 
Scale bars: 20 μm.
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Figure 8. TPM4 dose-dependently facilitates proplatelet formation. (A) Logistic regression analysis showing that the percentage of proplatelet-forming cells 
decreases with Tpm4 RNA (left; effect 1.22, P < 2–16) and protein (right; effect 2.54, P = 6.23–12) levels. Node size reflects the number of cells counted (at least 200). 
(B) Increased number of megakaryocytes (MK) in bone marrow from Tpm4Plt53/+ and Tpm4Plt53/Plt53 mice. Shown are results from 50 fields of view (FOV) (Tpm4+/+ 
and Tpm4Plt53/+) and 28 FOV (Tpm4Plt53/Plt53). (C) Representative pictures of H&E-stained bone marrow sections show altered morphology (smaller size, irregular 
shape) of Tpm4Plt53/+ and Tpm4Plt53/Plt53 megakaryocytes compared with the control (n = 3). Arrows indicate megakaryocytes. Scale bar: 15 μm. (D) Decreased size  
of Tpm4 mutant megakaryocytes compared with WT counterparts. n = 105 (Tpm4+/+), n = 35 (Tpm4Plt53/+), n = 125 (Tpm4Plt53/Plt53). (E) Left: Decreased proplatelet  
formation (PPF) of fetal liver cell–derived Tpm4Plt53/+ and Tpm4Plt53/Plt53 megakaryocytes (n = 5–6). Each dot represents the mean of 1 individual sample (at least  
12 visual fields counted). Right: Representative light microscopy pictures showing altered morphology and decreased branch formation of Tpm4Plt53/+ and  
Tpm4Plt53/Plt53 compared with Tpm4+/+ megakaryocytes. Scale bar: 50 μm. (F) Investigation of F-actin (red) and tubulin (green) distribution of proplatelet-forming 
Tpm4+/+ (left) and Tpm4Plt53/Plt53 (right) megakaryocytes by confocal immunofluorescence microscopy. Nuclei were stained with DAPI (blue). Scale bars: 20 μm. (B 
and E) One-way ANOVA, unpaired 2-tailed Student’s t test with Bonferroni correction for multiple comparisons. (D) One-way ANOVA, Mann-Whitney test with 
Bonferroni correction for multiple comparisons. **P < 0.01, ***P < 0.001.
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using ImageJ (NIH). Acute thrombocytopenia was induced by injec-
tion of antiplatelet serum and assessed as previously described (53).
Enumeration of hematopoietic progenitors in mice by flow cytometry
Organ cellularity was determined by counting of cell suspensions 
from bone marrow, spleen, and thymus with calibrate beads (BD 
Biosciences). Cells were stained on ice for 30 minutes, washed once, 
and then incubated with streptavidin–PE–Texas red (Life Technol-
ogies). After a washing step, acquisition was performed on an LSR 
Fortessa 1 (BD Biosciences) and analyzed with FlowJo (Tree Star). 
Antibodies for flow cytometry either were labeled in house with 
FITC, PE, PECy7, APC, or Alexa Fluor 700 or were biotinylated. 
CD4 (GK1.5), CD8 (53.6.7), CD16/32 (24G2), CD19 (1D3), CD41 
(MWReg30), Ter119 (Ly76), Gr1 (RB6-8C5), CD11b (M1/70), Sca1 
(D7), Kit (ACK4), B220 (RA3-6B2), and CD34-FITC (RAM34) were 
purchased from BD Pharmingen, and CD150-PE (TC15-12F12.2) was 
purchased from BioLegend. Fluorogold (Sigma-Aldrich) was used to 
exclude dead cells.
Investigation of the effect of the Plt53 mutation in megakaryocytes  
by RT-PCR
Fetal liver cell–derived megakaryocytes from Tpm4+/+, Tpm4Plt53/+, 
and Tpm4Plt53/Plt53 embryos E13.5 were generated as described below. 
mRNA was isolated using the RNeasy Plus Kit (Qiagen), and cDNA 
was synthesized using SuperScript III Reverse Transcriptase (Invit-
rogen) according to the manufacturer’s protocols. The primers used 
were 5′-AAAGAAGCCAAGCACATCAC-3′ (Tm4_F3) and 5′-AGC-
CCACATTCTCTTCTTTG-3′ (Tm4_R7). The expected product size 
Generation of Tpm4.2 knockout mice. Target sites in exon 1b of the 
mouse Tpm4 gene were analyzed by the MIT CRISPR Design Tool 
(51). Two high-scoring (>85) guide RNA (gRNA) sequences were cho-
sen, as they created a 93-bp deletion that interrupted the ATG start 
codon. The mouse oocytes were preincubated in cytochalasin B (5 μg/
ml); then 12.5 ng/μl of each commercially synthesized gRNA (Sigma- 
Aldrich) and 50 ng/μl of Cas9 mRNA were coinjected into the cyto-
plasm of mouse oocytes (52). Progeny were screened for the 93-bp 
deletion using the primers Tpm4.2 total KO forward 5′-GTGACCT-
CATGGGCCTGAC-3′ and Tpm4.2 total KO reverse 5′-GGACGA-
AAAGTGGGATCG-3′, which detects a WT allele of 317 bp and a 
knockout allele of 223 bp. DNA from founder mouse 6 had the expect-
ed 90-bp deletion, and a subsequent Western blot of tail lysates 
revealed the complete absence of TPM4.2, the sole TPM4 protein iso-
form expressed in mice.
Hematology
Human. Automated full blood cell counts were performed on blood 
collected by venipuncture into tubes containing EDTA using a Sysmex 
XN-1000 or XE-5000 hematological analyzer.
Mouse. Automated cell counts were performed on blood collected 
by cardiac puncture or from the retro-orbital plexus into Microtainer 
tubes containing EDTA (Sarstedt), using an Advia 2120 hematological 
analyzer (Siemens). Megakaryocytes were counted manually in sec-
tions of sternum stained with H&E with a minimum of 10 visual fields 
(×200) analyzed. Images were acquired on a Nikon Eclipse E600 
microscope equipped with AxioCam MRc5 (Zeiss) and AxioVision 4.8. 
Scale bars were inserted and the megakaryocyte area was determined 
Figure 9. TPM4-interacting proteins in megakaryocytes and platelets. (A) Investigation of cofilin and P-cofilin expression in Tpm4Plt53/Plt53 platelets (left) 
and fetal liver cell–derived megakaryocytes (right) by Western blot. Blots are representative of 2–3 individual experiments. (B) Densitometry analysis 
shows decreased levels of phosphorylated (inactive) cofilin in Tpm4Plt53/+ and Tpm4Plt53/Plt53 compared with Tpm4+/+ platelets (n = 6; results were pooled from 
2 separate experiments). (C) Investigation of NMMHC-IIa (green) and F-actin (red) localization in fetal liver cell–derived Tpm4+/+ and Tpm4Plt53/Plt53 mega-
karyocytes by confocal immunofluorescence microscopy. Scale bar: 20 μm. One-way ANOVA, unpaired 2-tailed Student’s t test with Bonferroni correction 
for multiple comparisons. *P < 0.05.
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Statistical analysis of the effect of TPM4 level on proplatelet 
formation in human megakaryocytes
To analyze the effect of TPM4 RNA and protein level on proplatelet 
formation, we performed logistic regression. A mixed-effects model 
was fitted to the log odds of a cell being proplatelet forming. A coef-
ficient was included representing the effect of an increase in RNA or 
protein levels on the log odds and was adjusted for cord effects using a 
random effect parameter.
Preparation of washed platelets
Mouse. Murine blood was obtained by cardiac puncture into 0.1 vol-
ume of Aster-Jandl anticoagulant (85 mM sodium citrate, 69 mM citric 
acid, and 20 mg/ml glucose, pH 4.6; ref. 54). Platelet-rich plasma was 
obtained by centrifugation at 125 g for 8 minutes, followed by centrif-
ugation of the supernatant buffy coat at 125 g for 8 minutes. Platelets 
were washed by 2 sequential centrifugations at 860 g for 5 minutes in 
140 mM NaCl, 5 mM KCl, 12 mM trisodium citrate, 10 mM glucose, 
and 12.5 mM sucrose, pH 6.0. The platelet pellet was resuspended in 




, 2.9 mM 
KCl, 12 mM NaHCO
3
, 5 mM HEPES, pH 7.4) containing 5 mM glucose, 
0.35% BSA, and 1 mM CaCl
2
.
Human. Platelet-rich plasma was obtained from citrated human 
whole blood by centrifugation at either 50 g for 10 minutes (patients) 
or 150 g for 20 minutes (controls). Platelets were washed by centrifu-
gation at 1,000 g for 10 minutes followed by resuspension in Tyrode-
HEPES buffer containing 5 mM glucose before a final spin at 1,000 g 
for 10 minutes.
Analysis of platelet activation and surface receptor expression  
by flow cytometry
Mouse. Washed platelets were adjusted to a concentration of 5 × 104 
per microliter and activated with the indicated agonists for 15 minutes 
at room temperature in the presence of JON/A–PE and anti–P-selec-
tin–FITC antibodies (diluted according to the manufacturers’ instruc-
tions). Samples were diluted with PBS and analyzed on a FACSCali-
bur. To assess platelet receptor expression, anticoagulated whole 
blood was diluted 1:20 using Tyrode-HEPES buffer and stained with 
platelet-specific antibodies or negative controls for 20 minutes at 
room temperature. Samples were diluted with Tyrode-HEPES buffer 
and directly acquired by flow cytometry.
Human. Citrated whole blood was incubated for 5 minutes 
with hirudin and aspirin, before being added to tubes containing 
HEPES-buffered saline, FITC–rabbit anti-fibrinogen antibody (Dako, 
F0111), and PE–mouse anti–P-selectin (IBGRL, clone Thromb6) or rel-
evant negative controls (P-selectin isotype, IBGRL, clone 9E10). Plate-
lets were agonized with a final concentration of 0.0005 μM ADP, 0.3 
μg/ml CRP-XL, and 0.8 μM TRAP-6 or left untreated. Apyrase was add-
ed to platelets agonized with CRP-XL and TRAP-6. Flow cytometry was 
performed on an FC-500 (Beckman Coulter), and platelets were identi-
fied by light scatter. Results were recorded as the percentage of platelets 
positive for the relevant activation marker.
Platelet spreading
Coverslips were coated with 100 μg/ml human fibrinogen and blocked 
with PBS 1% BSA. After rinsing with Tyrode-HEPES buffer, washed 
mouse platelets (100 μl with 0.03 × 106 platelets per microliter) were 
activated with 0.005 U/ml thrombin and incubated at room tempera-
for the WT was 360 bp, while an approximately 400-bp product was 
obtained in the presence of the Tpm4Plt53 allele. PCR products were 
sequenced and revealed the presence of an approximately 40-bp 
intronic inclusion in the mutant compared with the WT product.
Gene expression analysis in human megakaryocytes  
by RT–quantitative PCR
Total RNA was extracted using an RNeasy Plus Kit (Qiagen) accord-
ing to the manufacturer’s instructions. cDNA was prepared from 
250–500 ng total RNA using SuperScript III First-Strand Synthesis 
system for RT-PCR (Invitrogen) with random hexamers. Two-step 
quantitative PCR (qPCR) reactions were performed in duplicates 
using SYBR Green chemistry (Brilliant II SYBR Green QPCR Low 
ROX, Agilent Technologies) on an Mx3000P instrument (Agilent 
Technologies). Relative gene expression was calculated by the 
ΔΔCt method using GAPDH housekeeping gene for normaliza-
tion. PCR primer pairs were designed to amplify only cDNA, had 
no reported off-target matches searching the human NCBI RefSeq 
database, and were within 80%–120% PCR efficiencies with single 
dissociation curves.
qPCR oligonucleotide primer pairs were as follows: TPM1-F, 
AGTCGAGCCCAAAAAGATGA; TPM1-R, TCGCTCTCAATGATGA-
CCAG; TPM2-F, GGACAGAGGATGAGGTGGAA; TPM2-R, GCAT-
CAGTGGCCTTCTTCTC; TPM3-F, CCTGCAAAAGCTGGAAGAAG; 
TPM3-R, TCTGCCTCTTCTGCAATGTG; TPM4-F, GGAGATG-
CAGCTCAAAGAGG; TPM4-R, CCTCCAGGATGACCAGCTTA; 
GAPDH-F, TATCGTGGAAGGACTCATGACC; GAPDH-R, TAGAG-
GCAGGGATGATGTTCTG.
TPM4 knockdown in human megakaryocytes
Short hairpin vector cloning. Oligonucleotides were selected from 
the RNAi consortium database. Short hairpin or control nontarget 
sequences were annealed before cloning into the pLKO.1 lentiviral 
vector backbone (Addgene 10878) downstream of the human U6 pro-
moter and checked for sequence integrity.
Viral particle production. Replication-deficient lentiviral vector 
particles (LVPs) were produced by transient cotransfection of HEK 
293T/17 cells (ATCC CRL-11268) with pLKO.1–short hairpin con-
structs along with the psPAX2 and pMD2.G helper plasmids (Addgene 
12260, 12259) using TurboFect transfection reagent (Thermo Fisher 
Scientific). Crude supernatants containing LVPs were concentrated by 
PEG-based precipitation (LentiX-concentrator, Clontech) and func-
tional titers determined by qPCR measurement of provirus copy num-
ber in genomic DNA of transduced HCT116 cells (ATCC CCL-247).
Oligonucleotides used to construct short hairpin vectors. The following 
oligonucleotides were used to construct short hairpin vectors: TPM4_
shA forward, CCGGGGAAGAGGCTGACCGCAAATACTCGAG-
TATT TGCGGTCAGCCTCTTCCTTTTTG; TPM4_shA reverse, 
AAT TCAAAAAGGAAGAGGCTGACCGCAAATACTCGAGTATT
TGCGGTCAGCCTCTTCC; TPM4_shB forward, CCGGTCAGA-
CACTAAACGAACTTAACTCGAGTTAAGTTCGTTTAGTGTCT-
GATTTTTG; TPM4_shB reverse, AATTCAAAAATCAGACACTA-
A AC GA ACT TA ACTC GAGT TA AGT TC GT T TAGTGTCTGA; 
TPM4_shE forward, CCGGCCCAGTATCTAGTCGTGGATACTC-
GAGTATCCACGACTAGATACTGGGTTTTTG; TPM4_shE reverse, 
AATTCAAAAACCCAGTATCTAGTCGTGGATACTCGAGTATC-
CACGACTAGATACTGGG.
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under flow and analyzed data. KA designed and performed experi-
ments on mouse megakaryocytes and platelets and analyzed data. 
CL contributed to experiments on human megakaryocytes. RML 
contributed to animal experiments. GS interpreted results on the 
detection of tropomyosin isoforms. WSA and DJH contributed 
to the mouse ENU mutagenesis screen. WJA compared platelet 
parameters with distributions derived from INTERVAL data. KD 
performed functional analysis of human platelets. PN interpreted 
results from electron microscopy on human platelets. SKW and 
ADM recruited pedigree 1 and collected clinical phenotype data. 
SGO and PWC recruited pedigree 2 and collected clinical pheno-
type data. NIHR BioResource is a National Institute for Health 
Research research infrastructure that is responsible for the whole 
genome sequencing and phenotyping of 10,000 patients with rare 
diseases of unknown molecular etiology. FD, LMI, NSB, MH, and 
CAL generated and characterized the Tpm4.2 knockout mouse. 
ECH conceived and supervised the generation and characteriza-
tion of the Tpm4.2 knockout mouse. WHO directs the Bleeding 
and Platelet Disorders project of the NIHR BioResource–Rare 
Diseases. PWG contributed to the design and interpretation of 
experiments on the detection and function of tropomyosins. ET 
analyzed and interpreted human genetic, RNA, and proteomic 
data. MRT conceived the study in humans, designed experiments, 
interpreted data, and wrote the paper. BTK conceived the study, 
designed experiments, interpreted data, and wrote the paper.
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